PDCD1 and neoplasm: Interestingly, in the setting of excessive fat accumulation and lipotoxicity, the PD1 checkpoint inhibitors treatment leads to an expansion of intra-tumoral T lymphocytes (TIL), exacerbating liver damage and promoting tumor progression.